title: Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
abstract: A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed an adjunctive antiepileptic drug. The patients were followed up over a 6-month period. The interview included questions on Quality of Life, side-effects, adverse events and seizure frequency and severity. We operationally defined patients 'satisfaction' as (i) still on new drug; (ii) experiencing no side-effects (iii) experiencing no adverse events and (iv) had a greater than 50% reduction in seizures. A total of 13 patients (17%) reported being 'satisfied' according to our operational definition.
authors.affiliation: Raymond Way Neuropsychiatry Unit, Institute of Neurology, London, UK.
authors.forename: C E
authors.initials: CE
authors.lastname: Selai
authors.forename: M R
authors.initials: MR
authors.lastname: Trimble
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D001569:Benzodiazepines; D000078306:Clobazam; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D000077206:Gabapentin; D006306:Health Surveys; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D010349:Patient Compliance; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D014227:Triazines / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000085:Acetates; D000588:Amines; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D001569:Benzodiazepines; D000078306:Clobazam; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine